For people with diabetes taking glucose-lowering medications: Medication review : Your healthcare team should review and potentially reduce doses of insulin or sulphonylureas before starting Wegovy Blood glucose monitoring : Increase the frequency of self-monitoring, particularly before meals and at bedtime, especially during dose escalation Recognise patterns : Keep a diary noting blood glucose readings, meal times, and any symptoms to identify trends Adjust insulin doses : Work with your diabetes team to establish protocols for insulin dose adjustments based on readings and food intake Carry glucose : Always have fast-acting carbohydrates available (glucose tablets, juice, or sweets) to treat hypoglycaemia promptly For treating hypoglycaemia (for all at risk): Take 15-20g of fast-acting carbohydrate (e.g., 4-5 glucose tablets, 150-200ml fruit juice, or 5-6 jelly babies) Recheck blood glucose after 10-15 minutes If still below 4.0 mmol/L, repeat the fast-acting carbohydrate Once recovered, eat a longer-acting carbohydrate snack or meal (e.g., sandwich, cereal, or fruit with crackers) Those at risk of severe hypoglycaemia should have glucagon available and ensure family members know how to use it For people without diabetes: Regular meals : Despite reduced appetite, maintain a regular eating pattern with balanced meals containing adequate carbohydrates Recognise symptoms : Be aware of hypoglycaemia symptoms and don't dismiss them as general unwellness Avoid prolonged fasting : Whilst Wegovy reduces hunger, extended periods without food may trigger low blood sugar in susceptible individuals Moderate alcohol : Limit alcohol consumption and always consume it with food General strategies for all patients: Ensure adequate hydration, as Wegovy can cause gastrointestinal side effects that may affect fluid balance
Taking your GLP-1 injection or oral dose at the same time each day, eating smaller meals 23 hours before lying down, and avoiding acidic or high-fat trigger foods reduce mechanical and chemical contributors to reflux
Actual guidance based on body weight ranges, prior peptide experience, individual goals, and the tolerance patterns observed across hundreds of documented protocols
coli must be purified extensively, even if delivered orally
[1] [2] Strategic timing of tirzepatide administration may help some patients manage common adverse effects, particularly gastrointestinal symptoms that occur during initial treatment and dose escalation
Several ongoing clinical trials are investigating incretin-based therapies for alcohol use disorder, tobacco use disorder, and opioid use disorder
